These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1820457)
1. FDA issues draft 'concept paper' on drug company funding of CME. Skolnick A JAMA; 1991 Dec; 266(21):2947-8. PubMed ID: 1820457 [No Abstract] [Full Text] [Related]
2. Drug company sponsorship of education: the response to the FDA draft concept paper. Lazar EJ; Banks D; Graham C; Adams D; Rheinstein PH; Gross M; Witt AM JAMA; 1992 Jul; 268(1):53-4. PubMed ID: 1608109 [No Abstract] [Full Text] [Related]
3. Draft policy statement on industry-supported scientific and educational activities; notice. U.S. Food and Drug Administration Fed Regist; 1992 Nov; 57(229):56412-4. PubMed ID: 11645753 [No Abstract] [Full Text] [Related]
4. Kennedy hearings say no more free lunch--or much else--from drug firms. Randall T JAMA; 1991 Jan 23-30; 265(4):440, 442. PubMed ID: 1985222 [No Abstract] [Full Text] [Related]
5. Rule could mean higher risks for some children. Maloney DM Hum Res Rep; 1999 Feb; 14(2):3. PubMed ID: 11657603 [No Abstract] [Full Text] [Related]
6. Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines. Rosner F Mt Sinai J Med; 1995 Nov; 62(6):427-30. PubMed ID: 8692156 [TBL] [Abstract][Full Text] [Related]
8. Drug makers set off a bitter debate with ads aimed directly at patients. Rosenthal E N Y Times Web; 1991 Mar; ():34. PubMed ID: 11653935 [No Abstract] [Full Text] [Related]
9. FDA regulation of prescription drug advertising. Peck CC; Rheinstein PH JAMA; 1990 Nov; 264(18):2424-5. PubMed ID: 2232001 [No Abstract] [Full Text] [Related]
10. International research agreement leads to new U.S. guidelines. Maloney DM Hum Res Rep; 1995 Apr; 10(4):1-2. PubMed ID: 11654182 [No Abstract] [Full Text] [Related]
11. Pitching doctors. Wilkes MS; Shuchman M N Y Times Mag; 1989 Nov; ():88, 90, 126, 128-129. PubMed ID: 11650264 [No Abstract] [Full Text] [Related]
12. Perspectives on the FDA status of drug products manufactured by the recombinant DNA technique. Korwek EL; Trinker DS Food Drug Cosmet Law J; 1981 Oct; 36(10):517-35. PubMed ID: 11650658 [No Abstract] [Full Text] [Related]
13. FDA issues concerning conflicts of interest. Kurt TL IRB; 1990; 12(5):6-9. PubMed ID: 11654003 [No Abstract] [Full Text] [Related]
14. The federal regulation of prescription drug advertising and promotion. Kessler DA; Pines WL JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998 [TBL] [Abstract][Full Text] [Related]
15. Interactions between physicians and the health care technology industry. Tenery RM JAMA; 2000 Jan; 283(3):391-3. PubMed ID: 10647803 [No Abstract] [Full Text] [Related]
16. Corporate responsibility for recombinant DNA activities. Berger BA Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592 [No Abstract] [Full Text] [Related]
17. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials. Annas GJ Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162 [No Abstract] [Full Text] [Related]
18. Top manufacturer of gel implants replaces its chief. Hilts P N Y Times Web; 1992 Feb; ():A1, A18. PubMed ID: 11646914 [No Abstract] [Full Text] [Related]
19. The regulation of clinical investigators. Endries RN Food Drug Cosmet Law J; 1980 Jul; 35(7):415-23. PubMed ID: 11661860 [No Abstract] [Full Text] [Related]
20. Ethical perspectives on the FDA and ADA evaluation of dental products. Veatch RM J Public Health Dent; 1992; 52(6; Spec. Iss):387-90. PubMed ID: 11659654 [No Abstract] [Full Text] [Related] [Next] [New Search]